Retinal Drusen malady

Categories: Eye diseases

Aliases & Classifications for Retinal Drusen

Aliases & Descriptions for Retinal Drusen:

Name: Retinal Drusen 12 42 14 69


External Ids:

Disease Ontology 12 DOID:2569
ICD9CM 35 362.57
MeSH 42 D015593
UMLS 69 C0035312

Summaries for Retinal Drusen

MalaCards based summary : Retinal Drusen is related to basal laminar drusen and doyne honeycomb degeneration of retina. An important gene associated with Retinal Drusen is CFH (Complement Factor H), and among its related pathways/superpathways are Creation of C4 and C2 activators and Complement and coagulation cascades. The drugs Glatiramer Acetate and Adjuvants, Immunologic have been mentioned in the context of this disorder. Affiliated tissues include eye and kidney, and related phenotype is renal/urinary system.

Related Diseases for Retinal Drusen

Graphical network of the top 20 diseases related to Retinal Drusen:

Diseases related to Retinal Drusen

Symptoms & Phenotypes for Retinal Drusen

MGI Mouse Phenotypes related to Retinal Drusen:

id Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 8.92 C3 CFB CFH EFEMP1

Drugs & Therapeutics for Retinal Drusen

Drugs for Retinal Drusen (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Glatiramer Acetate Approved, Investigational Phase 2, Phase 3,Phase 1 147245-92-9 3081884
2 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1
3 Antirheumatic Agents Phase 2, Phase 3,Phase 1
4 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
5 Omega 3 Fatty Acid Nutraceutical Phase 3
Bevacizumab Approved, Investigational Phase 2 216974-75-3
Daclizumab Approved, Investigational Phase 2 152923-56-3
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
Infliximab Approved Phase 2 170277-31-3
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
Ranibizumab Approved Phase 2 347396-82-1 459903
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
Ephedrine Approved Phase 2 299-42-3 9294
Pseudoephedrine Approved Phase 2 90-82-4 7028
15 Angiogenesis Inhibitors Phase 2
16 Angiogenesis Modulating Agents Phase 2
17 Anti-Bacterial Agents Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 2,Phase 1
19 Antibodies Phase 2,Phase 1
20 Antifungal Agents Phase 2,Phase 1
21 Anti-Infective Agents Phase 2,Phase 1
22 Dermatologic Agents Phase 2
23 Gastrointestinal Agents Phase 2
24 Immunoglobulin G Phase 2
25 Immunoglobulins Phase 2,Phase 1
26 Complement System Proteins Phase 2,Phase 1
27 Antioxidants Phase 2
28 Autonomic Agents Phase 2
29 Nasal Decongestants Phase 2
30 Ophthalmic Solutions Phase 2
31 Peripheral Nervous System Agents Phase 2
32 Pharmaceutical Solutions Phase 2
33 Protective Agents Phase 2
34 Respiratory System Agents Phase 2
35 Tetrahydrozoline Phase 2
36 Vasoconstrictor Agents Phase 2
37 Endothelial Growth Factors Phase 2
38 Mitogens Phase 2
39 Vaccines Phase 1
Copper Approved 15158-11-9, 7440-50-8 27099
Zinc Approved 7440-66-6 32051 23994
Heparin Approved, Investigational 9005-49-6 772 46507594
Dipivefrin Approved 52365-63-6 3105
Lutein Approved, Nutraceutical 127-40-2 6433159 5368396
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
Melatonin Approved, Nutraceutical, Vet_approved 73-31-4 896
48 Tocopherols
49 Tocotrienols
50 Vitamins

Interventional clinical trials:

(show all 43)
id Name Status NCT ID Phase
1 Copaxone in Age Related Macular Degeneration Unknown status NCT00466076 Phase 2, Phase 3
2 Complications of Age-Related Macular Degeneration Prevention Trial Completed NCT00000167 Phase 3
3 Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Suspended NCT00460967 Phase 3
4 Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD). Terminated NCT00987129 Phase 3
5 Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD Unknown status NCT00684853 Phase 2
6 Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration Completed NCT00304954 Phase 2
7 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed NCT00935883 Phase 2
8 A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration Completed NCT00447954 Phase 2
9 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD Completed NCT00766649 Phase 1, Phase 2
10 Sirolimus for Advanced Age-Related Macular Degeneration Completed NCT01445548 Phase 1, Phase 2
11 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Completed NCT00306488 Phase 2
12 Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) Completed NCT01535950 Phase 2
13 Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) Completed NCT01527500 Phase 2
14 Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD). Terminated NCT01624636 Phase 2
15 Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration Completed NCT00001615 Phase 1
16 Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration Completed NCT01255462 Phase 1
17 Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59 Recruiting NCT03144999 Phase 1
18 An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration Recruiting NCT02848313 Phase 1
19 Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration Suspended NCT00541333 Phase 1
20 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
21 Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye Unknown status NCT01348672
22 Non-exudative Age-related Macular Degeneration Unknown status NCT01712841
23 Retinal Neurodegenerative Signs in Alzheimer's Diseases Unknown status NCT01555827
24 A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population Completed NCT01666821
25 Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography Completed NCT01272063
26 Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation Completed NCT01890174
27 Prophylactic Laser Treatment of Drusen Maculopathy Completed NCT00348543
28 AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study Completed NCT00734487
29 Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation Completed NCT02264938
30 Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation Completed NCT00808197
31 Genetic Assessment of Early to Late Macular Degeneration Study Completed NCT01464710
32 HELP Therapy for Dry AMD Completed NCT01840683
33 "Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study Recruiting NCT02960828
34 Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration Recruiting NCT02569892
35 GARM II: A Study on the Genetics of Age-related Maculopathy Recruiting NCT01115387
36 Spectral Domain OCT Imaging in Patients With Optic Nerve Head Drusen (Tuebingen SD-OCT IN OPTIC NERVE HEAD DRUSEN STUDY) Active, not recruiting NCT02793206
37 Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease Active, not recruiting NCT01937221
38 Study on Visual Function Impairments in Dry Age-related Macular Degeneration Active, not recruiting NCT01822873
39 Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy Active, not recruiting NCT00393692
40 Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study Active, not recruiting NCT02390245
41 AMD Ryan Initiative Study (ARIS) Not yet recruiting NCT03092492
42 Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin Terminated NCT00444249
43 Risk Factors for Drusen Progression Withdrawn NCT01830608

Search NIH Clinical Center for Retinal Drusen

Cochrane evidence based reviews: retinal drusen

Genetic Tests for Retinal Drusen

Anatomical Context for Retinal Drusen

MalaCards organs/tissues related to Retinal Drusen:

Eye, Kidney

Publications for Retinal Drusen

Articles related to Retinal Drusen:

id Title Authors Year
Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying Retinal Drusen. ( 26871693 )
Chronic kidney disease, early age-related macular degeneration, and peripheral retinal drusen. ( 22053834 )
Peripheral retinal drusen and reticular pigment: association with CFHY402H and CFHrs1410996 genotypes in family and twin studies. ( 18936151 )
Retinal drusen: harbingers of age, safe havens for trouble. ( 19726434 )
IDOCS: intelligent distributed ontology consensus system--the use of machine learning in retinal drusen phenotyping. ( 17460291 )
New developments in retinal drusen. ( 9692044 )

Variations for Retinal Drusen

Expression for Retinal Drusen

Search GEO for disease gene expression data for Retinal Drusen.

Pathways for Retinal Drusen

GO Terms for Retinal Drusen

Cellular components related to Retinal Drusen according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.63 C2 C3 CFB CFH EFEMP1 FBLN5
2 blood microparticle GO:0072562 9.43 C3 CFB CFH
3 extracellular region GO:0005576 9.43 C2 C3 CFB CFH EFEMP1 FBLN5
4 extracellular space GO:0005615 9.1 C2 C3 CFB CFH EFEMP1 FBLN5

Biological processes related to Retinal Drusen according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.62 C2 C3 CFB CFH
2 regulation of complement activation GO:0030449 9.46 C2 C3 CFB CFH
3 positive regulation of apoptotic cell clearance GO:2000427 9.26 C2 C3
4 complement activation GO:0006956 9.26 C2 C3 CFB CFH
5 complement activation, alternative pathway GO:0006957 8.8 C3 CFB CFH

Molecular functions related to Retinal Drusen according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 8.8 C2 C3 CFB

Sources for Retinal Drusen

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....